All News
Filter News
Found 771 articles
-
IVI, INOVIO, and KNIH to Partner with CEPI in Phase 1/2 Clinical Trial of INOVIO's COVID-19 DNA Vaccine in South Korea
4/16/2020
The Coalition for Epidemic Preparedness Innovations (CEPI) grants $6.9 million funding to INOVIO and IVI to conduct clinical testing in Korea for INOVIO's COVID-19 vaccine candidate based on their well-established DNA platform technology
-
INOVIO to Host its Annual Meeting of Stockholders in Virtual Format and at a New Time
4/15/2020
INOVIO Pharmaceuticals, Inc. (NASDAQ:INO) today announced that due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic and recommendations and orders from federal and state governmental authorities, its Annual Meeting of Stockholders (the 2020 Annual Meeting) will now be held by means
-
Cellectis Appoints Carrie Brownstein, M.D., as Chief Medical OfficerIndustry veteran joins Cellectis leadership team as UCART product pipeline advances in clinical trials
4/13/2020
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced the appointment of Carrie Brownstein, M.D., to the role of Chief Medical Officer
-
2020 Diabetic Foot Ulcers Treatment Market | Acelity, Medtronic, Coloplast
4/13/2020
The demand in the global diabetic foot ulcers treatment market is expected to increment at a healthy CAGR during the forecast period of 2020 to 2029, gaining traction from a number of factors such as rising percentage of geriatrics in the world population, the prevalence of target diseases, growing demand for early detection of incurable diseases, and the presentation of innovative applications.
-
Medical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Receives Notice of Allowance from USPTO for Trademark of Atopidine™
4/9/2020
Medical Marijuana, Inc. (OTC: MJNA) (the "Company"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its investment company Kannalife, Inc. ("Kannalife") (OTCQB: KLFE),
-
Roche Tops the Pharmaceutical Innovation Index for the First Time; AstraZeneca Ranks 1st for Its Pipeline
4/8/2020
The tenth annual Pharmaceutical Innovation Index, released by IDEA Pharma today, sees Roche top the industry for the first time.
-
INOVIO Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine and Plans First Dose Today
4/6/2020
- Up to 40 Healthy Volunteers To Participate at Two Trial Locations - Preclinical Animal Studies Show Promising Immune Responses - Rapid Advancement Possible Through a Global Coalition of Collaborators, Partners, and Funders
-
Alnylam and Dicerna Form RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Associated Liver Disease and Complete Cross-License Agreement for Primary Hyperoxaluria Programs
4/6/2020
April 6, 2020 11:00 UTC - Dicerna to Lead Global Clinical Development and U.S. Commercialization of its DCR-A1AT and Alnylam’s ALN-AAT02 Investigational Therapeutics for the Treatment of Alpha-1 Liver Disease; Alnylam Retains Post-Phase 3 Opt-in Right for Ex-U.S. Commercialization - - Companies Complete Non-Exclusive Intellectual Property Cross-License Agreement for the Development and Commercialization of Alnylam’s Lumasiran and Dicerna’s Nedosiran Investigational Programs f
-
Novartis announced that, with Incyte, it is launching a Phase III clinical trial to determine if their cancer drug Jakavi (ruxolitinib) can be used to treat COVID-19.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 1, 2020.
-
The companies initiated a Phase II/III trial in Italy, Spain, Germany, France, Japan, Canada and Russia.
-
Kannalife, Inc. Receives Notice of Allowance from USPTO for Trademark of Atopidine™
4/1/2020
Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the Company has been issued a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its trademark application for the mark, “Atopidine”. The Company chose Atopidine™ as the trademark for Limonenyldihydroxybenzyl E
-
UPDATE – Kannalife, Inc. Receives Notice of Allowance from USPTO for Trademark of Atopidine™
4/1/2020
Kannalife, Inc., a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced that the Company has been issued a Notice of Allowance from the United States Patent and Trademark Office for its trademark application for the mark, “Atopidine”.
-
INOVIO Interim Results of an Open-Label Phase 2 Trial of VGX-3100 Show Efficacy Against HPV-associated Vulvar Dysplasia
3/30/2020
- VGX-3100 DNA medicine reduced qualifying high-risk HPV 16/18-associated precancerous vulvar lesion area in 80% of patients (by 60% on average); completely curing vulvar dysplasia with no virus detectable in 20% of patients - Data to be presented at the 2020 American Society for Colposcopy and Cervical Pathology (ASCCP) meeting [30-March-2020] PLYMOUTH MEETIN
-
INOVIO Reports Positive Interim Phase 2 VGX-3100 Results In Patients with HPV-associated Anal Dysplasia
3/26/2020
- VGX-3100 DNA medicine cleared high-risk HPV 16/18-associated precancerous lesions in 50% of patients, and reduced the number of lesions in 75% of patients - Data to be presented at the 2020 American Society for Colposcopy and Cervical Pathology (ASCCP) meeting [26-March-2020] PLYMOUTH MEETING, Pa. , March 26, 2020 /PRNewswire/ -- INOVIO Pharmaceuticals, In
-
Ology Bioservices, Inovio Partner To Manufacture COVID-19 DNA Vaccine With $11.9 Million Department of Defense Grant
3/24/2020
Ology Bioservices Inc. and Inovio Pharmaceuticals Inc. announced that the Department of Defense has awarded Ology Bioservices with a contract valued at $11.9 million to work with Inovio on DNA technology transfer to rapidly manufacture DNA vaccines.
-
As the world and biopharma grapple with developing vaccines and drugs against COVID-19, researchers are turning to a handful of drugs that show particular promise. Several of those drugs are by companies with offices or headquarters in the San Francisco Bay Area. Here’s a look.
-
The company has initiated a late-stage trial assessing its rheumatoid arthritis drug Actemra in patients who have severe COVID-19 caused pneumonia.
-
Regeneron said it has identified hundreds of virus-neutralizing antibodies and intends to begin large-scale manufacturing by mid-April.
-
As the number of diagnosed cases of COVID-19 continue to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection ...